Skip to main content
OpenTrials
Completed

NCT Number: NCT01609413

The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement

In a crossover, single blind, randomized trial the calcium bioavailability of two calcium supplements will be compared.That is AlgaeCal®(Algaecal Inc, Vancouver, Canada)(1 dose is 3 capsules of 180 mg calcium), derived from ocean algae and the proprietary calcium supplement Caltrate 600® (Wyeth Consumer Healthcare, Inc).

After a screening visits 20 healthy male subjects aged 20-50 years will spend a day at the research center to examine calcium bioavailability data. They will be randomized to consume either first the AlgaeCal® supplement or the Caltrate 600® supplement. After a one week wash-out period subjects will be supplemented with the other supplement. During the examination day blood and urine samples will be collected before and until eight hours after the supplementation for analyses of calcium, creatinine, phosphorus, albumin and 25 Hydroxy vitamin D. Subjects are instructed to avoid taking calcium and/or vitamin D supplements 1 week before and during the entire study period. In addition, they are not allowed to take medication that may affect calcium metabolism.

The hypothesis of the study is that calcium bioavailability of the AlgaeCal® supplement will be higher than that of the Caltrate 600® supplement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

20 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Luigi Sacco Hospital

Milan, 20157, Italy

About this study

This was a single centre, single-dose, randomized, two way cross-over study in healthy male subjects.

The study consisted of the following visits:

  • A screening visit to select eligible subjects according to the inclusion/exclusion criteria detailed in the study protocol.
  • Visit 1 in which subjects who satisfied the selection criteria were assigned to one of the two intervention sequences (Algaecal®/ LCCS or LCCS/Algaecal®) according to the randomization list;
  • Visit 2, after at least one week of wash-out in respect to visit 1. Subjects arrived at the centre early in the morning The first blood sample was drawn before the ingestion of the calcium supplement and every hour after for the following 8 hours. Urine sample were collected before the ingestion of the calcium supplement and every 2 hours after for the following 8 hours. During each study visit the subjects were present in the site centre from the morning to the evening. Calcium supplement was given under fasted condition and during the eight hours after the product ingestion, according to the protocol, only water ad libitum was allowed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy free-living men aged 20 to 50 years-old
  • Consent to the study and compliance with study product

Exclusion criteria

  • Calcium supplements or calcitriol taken one week or less before the first kinetic visit
  • Heart disease
  • Circulation problems
  • Parathyroid gland disorder
  • Kidney disease
  • Past or present kidney stones
  • Gastrointestinal disturbances that could potentially affect the absorption of calcium supplements

Treatment and study plan

AlgaeCal

Dietary Supplement

One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.

Caltrate 600

Dietary Supplement

One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.

Primary outcomes

  1. Will be measured the oral bioavailability of calcium from a single dose of AlgaeCal® (Algaecal, Vancouver, Canada) compared to a proprietary calcium supplement (Caltrate 600®, Whyett Consumer healthcare, Inc).

    Time frame: one day

    During the examination day blood and urine samples will be collected before and untill eight hours after the supplementation for analyses of calcium, creatinine, phosphorus, albumin and 25 Hydroxy vitamin D.

Sponsors and collaborators

Lead sponsor

Sprim Italia

Unknown

Collaborators

  • AlgaeCal Inc.

Registry information

Official study title

A Human Crossover Study to Compare the Bioavailability of Calcium From AlgaeCal® Versus a Proprietary Calcium Dietary Supplement

Acronym: COMCAL

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jun 1, 2012
Registry last updated
Jun 1, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.